Format

Send to

Choose Destination
BMJ. 2018 Nov 1;363:k4383. doi: 10.1136/bmj.k4383.

Reporting harms more transparently in trials of cancer drugs.

Author information

1
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Japan.
2
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
PMID:
30385466
DOI:
10.1136/bmj.k4383
[Indexed for MEDLINE]

Conflict of interest statement

Competing interests: We have read and understood BMJ policy on declaration of interests and declare that BG is an adviser to the BMJ analysis team. YA has received research funding and personal fees from drug companies but none in relation to this work.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center